Bcma chimeric antigen receptors
Assignee2seventy bio, Inc.
InventorsRichard Morgan, Kevin Friedman
Life of this patent
Estimating the term…
Abstract
The invention provides improved compositions for adoptive T cell therapies for B cell related conditions.
Claims41
-65. (canceled)
A method of treating a B cell malignancy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of human immune effector cells that express a chimeric antigen receptor (CAR) comprising amino acids 22-493 of the amino acid sequence set forth in SEQ ID NO:
- 9.
A method of treating a B cell malignancy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of human immune effector cells comprising a vector comprising a polynucleotide that encodes a CAR comprising amino acids 22-493 of the amino acid sequence set forth in SEQ ID NO:
- 9.
A method of treating a B cell malignancy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising a physiologically acceptable excipient and human immune effector cells;
- wherein the immune effector cells comprise a lentiviral vector;
- wherein the lentiviral vector comprises a left (5′) lentiviral LTR wherein the promoter of the 5′ LTR is replaced with a CMV promoter;
- a Psi (Ψ) packaging signal;
- a cPPT/FLAP;
- a Rev response element (RRE);
- a myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted (MND) promoter operably linked to a polynucleotide encoding a CAR comprising amino acids 22-493 of the amino acid sequence set forth in SEQ ID NO:
- 9;
- a right (3′) lentiviral self-inactivating (SIN) LTR;
- and a heterologous polyadenylation sequence.
A method of treating multiple myeloma (MM) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of human immune effector cells that express a CAR comprising amino acids 22-493 of the amino acid sequence set forth in SEQ ID NO:
- 9.
A method of treating a B cell malignancy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of human immune effector cells comprising a CAR comprising:
- a) means for binding B cell maturation antigen (BCMA) and;
- b) amino acids 271-493 of the amino acid sequence set forth in SEQ ID NO:
- 9.
Dependencies are inferred from the claim text.